Mariana Diupotex, Veronica Rojo-Leon, Luis Eduardo Chipres-Naranjo, Estefanía Alemán-Navarro, Emiliano Rubio-Blancas, Alejandra Carrillo-Carlos, Gabriel Ramírez-Vilchis, Jazmin López-Acosta, José Luis Maravillas-Montero, Yvonne Rosenstein
{"title":"CD43: recent advances and emerging functions.","authors":"Mariana Diupotex, Veronica Rojo-Leon, Luis Eduardo Chipres-Naranjo, Estefanía Alemán-Navarro, Emiliano Rubio-Blancas, Alejandra Carrillo-Carlos, Gabriel Ramírez-Vilchis, Jazmin López-Acosta, José Luis Maravillas-Montero, Yvonne Rosenstein","doi":"10.1093/jleuko/qiag084","DOIUrl":null,"url":null,"abstract":"<p><p>Originally characterized for its roles in T-cell activation and adhesion, CD43 is a prominent mucin-like sialoglycoprotein expressed on hematopoietic cells. CD43 is broadly expressed across leukocyte populations, with its levels, molecular configuration, and ligand interactions varying by cell type, activation state, and differentiation. Growing evidence indicates that CD43 functions as a context-dependent regulator, integrating microenvironmental cues and dynamic glycosylation states with the biophysical organization of the cell surface and intracellular signaling. CD43 simultaneously participates in immune activation, regulation, and dysfunction, depending on the cellular and environmental context. CD43 is associated with distinct, sometimes contrasting, functional outcomes across diverse physiological and pathological settings. For instance, it has been linked to altered leukocyte trafficking and activation, while in infectious diseases, it influences host-pathogen interactions and the balance between protective immunity and immunopathology. Furthermore, in cancer, changes in CD43 signaling, glycosylation, and ligand engagement modulate immune recognition, effector responses, and inflammatory processes, contributing to immune evasion. Here, we review current knowledge on the regulation of CD43 expression, its structural organization, and ligand interactions. We discuss the potential role of CD43 across different disease settings, proposing it as a dynamic, adaptable regulator of immune responses and a potential therapeutic target in immune-mediated diseases.</p>","PeriodicalId":16186,"journal":{"name":"Journal of Leukocyte Biology","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Leukocyte Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jleuko/qiag084","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Originally characterized for its roles in T-cell activation and adhesion, CD43 is a prominent mucin-like sialoglycoprotein expressed on hematopoietic cells. CD43 is broadly expressed across leukocyte populations, with its levels, molecular configuration, and ligand interactions varying by cell type, activation state, and differentiation. Growing evidence indicates that CD43 functions as a context-dependent regulator, integrating microenvironmental cues and dynamic glycosylation states with the biophysical organization of the cell surface and intracellular signaling. CD43 simultaneously participates in immune activation, regulation, and dysfunction, depending on the cellular and environmental context. CD43 is associated with distinct, sometimes contrasting, functional outcomes across diverse physiological and pathological settings. For instance, it has been linked to altered leukocyte trafficking and activation, while in infectious diseases, it influences host-pathogen interactions and the balance between protective immunity and immunopathology. Furthermore, in cancer, changes in CD43 signaling, glycosylation, and ligand engagement modulate immune recognition, effector responses, and inflammatory processes, contributing to immune evasion. Here, we review current knowledge on the regulation of CD43 expression, its structural organization, and ligand interactions. We discuss the potential role of CD43 across different disease settings, proposing it as a dynamic, adaptable regulator of immune responses and a potential therapeutic target in immune-mediated diseases.
期刊介绍:
JLB is a peer-reviewed, academic journal published by the Society for Leukocyte Biology for its members and the community of immunobiologists. The journal publishes papers devoted to the exploration of the cellular and molecular biology of granulocytes, mononuclear phagocytes, lymphocytes, NK cells, and other cells involved in host physiology and defense/resistance against disease. Since all cells in the body can directly or indirectly contribute to the maintenance of the integrity of the organism and restoration of homeostasis through repair, JLB also considers articles involving epithelial, endothelial, fibroblastic, neural, and other somatic cell types participating in host defense. Studies covering pathophysiology, cell development, differentiation and trafficking; fundamental, translational and clinical immunology, inflammation, extracellular mediators and effector molecules; receptors, signal transduction and genes are considered relevant. Research articles and reviews that provide a novel understanding in any of these fields are given priority as well as technical advances related to leukocyte research methods.